Latest News

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer
T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

April 21st 2025

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.
Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

April 21st 2025

Video Series
Video Interviews
Podcasts
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Early screening for breast cancer may help match patients with appropriate systemic therapies depending on the extent of their tumors, according to Rakhshanda Rahman, MD, FRCS, FACS.
Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

More News